COMPLEXES OF SIROLIMUS AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The invention is directed to a stable complex with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Sirolimus or derivatives thereof, which is useful in in the prophylaxis of organ rejection in patients receiving renal transplants, in the treatment of psoriasis, facial angiofibromas associated with tuberous sclerosis, fibrofolliculomas found in Birt-Hogg-Dubé Syndrome, chronic erosive oral lichen planus, Early Stage Cutaneous T-cell Lymphoma, Treatment of Autoimmune Active Anterior Uveitis, dry eye syndrome, age-related macular degeneration, diabetic macular edema, noninfectious uveitis, telangiectasia, inflammatory skin diseases (dermatitis, including psoriasis and lichen ruber planus), Pachyonychia Congenita and in the suppression of angiogenesis pathways. More specifically, the complex of the present invention possesses increased apparent solubility, permeability and enhanced biological performance including significantly improved exposure, earlier tmax, higher Cmax and higher trough concentrations at 24 hours which will allow the reduction of the dose. Furthermore, the complex of the present invention possesses exceptional stability as a redispersed solution allowing the development of liquid based formulation for transdermal and other topical applications. The invention also relates to methods of formulating and manufacturing complex according to the invention, pharmaceutical compositions containing it, its uses and methods of treatment using the complex and its compositions. L'invention concerne un complexe stable présentant une taille particulaire contrôlée, une solubilité apparente accrue et une vitesse de dissolution accrue, comprenant à titre de composé actif le sirolimus ou des dérivés de celui-ci, qui est/sont utile(s) dans la prophylaxie du rejet d'organe chez des patients recevant des transplantations rénales, dans le traitement du psoriasis, des angiofibromes faciaux associés à la sclérose tubéreuse, des fibrofolliculomes du syndrome de Birt-Hogg-Dubé, du lichen plan buccal inflammatoire chronique, du lymphome T cutané à un stade précoce, le traitement de l'uvéite active antérieure auto-immune, du syndrome de l'oeil sec, de la dégénérescence maculaire liée à l'âge, de l'oedème maculaire diabétique, de l'uvéite non infectieuse, de la télangiectasie, des maladies cutanées inflammatoires (la dermatite, notamment le psoriasis et le lichen plan), de la pachyonychie congénitale et